Abbott Laboratories (NYSE:ABT) is highlighted as one of the best medical device stocks to invest in, with Benchmark initiating coverage on October 10 with a Buy rating and a $145 price target. The firm praises Abbott’s unique business strategy that is not dependent on any single treatment, product, or market.

Benchmark forecasts a resurgence in Abbott’s Diagnostics business in 2026 with the launch of a new molecular nucleic acid testing platform for blood screening. Despite post-pandemic testing declines and procurement pressures in China, Abbott is expected to rebound.

In addition to its medical device offerings, Abbott Laboratories (NYSE:ABT) is a prominent global healthcare company producing branded generic medications, diagnostics, and nutritional products. The company has shown resilience to potential trade disruptions through significant investments in new U.S. facilities.

While Abbott is a solid investment option, some analysts point to potentially greater upside in certain AI stocks with lower downside risk. Investors seeking opportunities in AI stocks impacted by tariffs and onshoring trends are advised to explore other options beyond Abbott.

Read more at Yahoo Finance: Abbott Laboratories (ABT) Rated Buy as Benchmark Highlights Diagnostics Growth and Global Resilience